查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1981456

免疫疗法药物市场：2026年至2032年全球市场预测（依治疗方法、给药途径、作用机制、最终用户和适应症划分）

Immunotherapy Drugs Market by Therapy Type, Route Of Administration, Mechanism Of Action, End User, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，免疫疗法药物市场价值将达到 2,225.9 亿美元，到 2026 年将成长至 2,515.6 亿美元，到 2032 年将达到 5,438.2 亿美元，年复合成长率为 13.61%。

主要市场统计数据
基准年 2025 2225.9亿美元
预计年份：2026年 2515.6亿美元
预测年份 2032 5438.2亿美元
复合年增长率 (%) 13.61%

本报告首先对免疫疗法的现状进行了简要概述。报告清晰阐述了研究范围、目标以及用于检验科学进展、临床进展、监管趋势和商业性发展的分析方法。此外，报告也为后续分析奠定了基础，包括临床疗效趋势、生产技术演进、供应链考量、监管观点以及推动相关人员采纳的因素。透过儘早建构这些框架，本报告引导读者了解相互关联的主题，这些主题将指南研究、临床应用、生产规模化和市场准入等各个环节的策略决策。

在调查方法方面，本导言阐述了建构一致证据基础的方法，该方法整合了专家访谈、临床资料库审查、监管文件、专利分析和真实世界资料（REW）。此外，本导言还概述了资料三角验证的假设以及评估技术成熟度和部署准备度的标准。这使得本报告成为决策者将科学研究机会与实际操作能力和政策现实结合的实用工具。

变革性的变化重新定义了临床范式和投资者的优先事项，重塑了免疫疗法的研究、生产、商业化和患者获取途径。

近年来，免疫疗法的研究重点、商业化路径和病患给药系统都发生了变革性变化。精准细胞工程技术的进步，例如新一代受体设计和同种异体移植平台，正在开拓更广泛的治疗概念，并提升现货产品的潜力。同时，疫苗平台、溶瘤载体和免疫调节剂的突破性进展正在融合形成多模态疗法，改变临床开发策略的设计和监管互动的方式。这些科学变革也伴随着营运层面的变革。模组化生产、一次性技术和分散式生产模式正在重新定义生产力计画和成本结构。

2025 年美国实施的关税措施对供应链、製造、临床试验和患者获得免疫疗法的累积影响。

美国2025年实施的关税措施的累积影响将对免疫疗法供应链、生产经济和临床营运整体造成一系列复杂的压力。进口试剂、特殊耗材、细胞处理设备和某些生物中间体的关税相关成本增加，将直接对製造商和合约研发生产机构（CDMO）构成业务阻力。由于先进疗法生产中的许多组件仍然依赖全球采购，这些额外成本可能会促使企业进行策略调整，例如重新评估供应商合约以降低风险、加强垂直整合以及加快本地化进程。因此，在选择製造地时，地缘政治风险将日益优先于成本和监管方面的考量。

针对治疗方法、适应症群、给药途径、最终使用者和作用机制的实用细分见解，可用于临床和商业规划。

精准理解细分市场对于将研发策略与临床需求和商业性路径相匹配至关重要。在考虑治疗方法类型时，整体情况，疗法包括细胞疗法、癌症疫苗、查核点抑制剂、细胞激素和溶瘤病毒疗法。在细胞疗法中，必须关注CAR-T疗法、NK细胞疗法和TCR-T疗法等子类别，因为每种疗法在生产、监管和给药方面都面临着独特的挑战。癌症疫苗包括树突细胞疫苗、DNA疫苗和胜肽疫苗，它们在抗原选择、佐剂需求和给药物流方面各不相同。查核点抑制剂包括CTLA-4抑制剂、PD-1抑制剂和PD-L1抑制剂，每种抑制剂都有其独特的疗效和毒性特征，这决定了联合治疗策略。细胞激素疗法，包括集落刺激因子、干扰素和白细胞介素，作为免疫反应调节剂和联合治疗的组成部分，继续发挥至关重要的作用。溶瘤病毒疗法，包括基于腺病毒、疱疹病毒和呼肠孤病毒的疗法，在载体设计、生产过程中的防护措施和免疫分析方面提出了独特的考虑因素。

对全球主要地区的采用趋势、基础设施发展、监管环境和市场进入进行区域性深入分析。

区域趋势影响全球技术采纳轨迹、基础建设、监管参与以及市场进入方式。在美洲，领先的研究中心汇聚了学术领导、製造专长和支付方合作关係，是先进医学发展的重要促进者。这些生态系在支持快速临床应用的同时，也凸显了将高度复杂的治疗方法整合到常规诊疗路径中，并与支付者协商基于价值的支付安排的必要性。

竞争考察检验产品线结构、策略联盟、製造能力、监管地位、商业化路径。

免疫疗法领域的竞争格局呈现出多元化的特点，既有成熟的製药公司，也有生物技术创新者、专业契约製造和学术联盟。拥有差异化平台、将独特生物学特性与可扩展生产优势相结合的公司占据主导地位，而那些致力于产生可靠临床证据并在真实临床环境中评估疗效的机构则正在与支付方和临床医生建立长期信任。策略联盟、授权协议和有针对性的收购仍然是加速获取载体生产、自动化细胞处理和伴随诊断等互补能力的关键手段。

为产业领导者提供切实可行的策略建议，以加速临床开发、提高生产韧性并实现患者公平获得治疗。

行业领导者应采取一系列优先策略步骤，将科学进步与永续的患者用药联繫起来。首先，各机构需要将临床开发与可生产性结合，在药物发现早期阶段就纳入製程开发，并检验可扩展的「品质源自于设计 (QbD)」生产方法。这将降低下游风险，并使与监管机构的互动更具可预测性。其次，相关人员应透过供应商多元化、认证替代来源以及探索区域生产伙伴关係关係来投资供应链韧性，从而减轻地缘政治因素和关税的干扰。

采用严谨的混合方法调查方法，结合一手访谈、临床资料库审查、监管分析和真实世界资料（REW）整合。

本调查方法采用混合方法，将质性专家访谈与临床註册资料、监管文件和科学文献的量化分析结合。主要研究包括与临床研究人员、生产企业负责人、监管专家、保险公司代表和患者权益倡导团体进行结构化讨论，以识别现实世界中的挑战和推动技术应用的因素。次要资讯则来自同行评审期刊、临床试验註册资料、监管指导文件、专利申请和公开讯息，用于检验趋势并进行交叉验证。

全面整合研究成果、策略意义和优先行动，指明免疫疗法创新和普及的未来方向。

总之，免疫疗法在科学和应用方面持续进步，相关人员必须将技术潜力与实际应用结合，才能真正造福患者。从精密的细胞工程和模组化製造到先进的疫苗和溶瘤病毒平台，科学创新正在拓展治疗选择，但要使这些疗法真正融入常规医疗保健，稳健的生产体系、数据驱动的报销策略以及与区域基础设施和法规结构的协调一致至关重要。关税和地缘政治因素带来的成本压力，使得供应链多角化和在地化工作更加紧迫，也凸显了战略远见的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法分類的免疫疗法药物市场

  • 过继性细胞疗法
    • CAR-T疗法
    • NK细胞疗法
    • TCR-T疗法
  • 癌症疫苗
    • 树突细胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 细胞激素
    • 集落刺激因子
    • 干扰素
    • 白细胞介素
  • 溶瘤病毒疗法
    • 基于腺病毒的
    • 疱疹病毒基础
    • 基于呼肠孤病毒

第九章：免疫疗法药物市场：依给药途径划分

  • 瘤内给药
  • 静脉
  • 皮下

第十章：免疫疗法药物市场依作用机制划分

  • 主动免疫治疗
  • 被动免疫疗法

第十一章 免疫疗法药物市场：依最终用户划分

  • 医院
  • 肿瘤诊所
  • 专业设施

第十二章 免疫疗法药物市场：依适应症划分

  • 血癌
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 淋巴瘤
  • 乳癌
    • 荷尔蒙受体阳性
    • 三重否定
  • 肺癌
    • 非小细胞肺癌
    • 小细胞肺癌
  • 恶性黑色素瘤
    • 皮肤黑色素瘤
    • 葡萄膜黑色素瘤

第十三章 免疫疗法药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 免疫疗法药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 免疫疗法药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国免疫疗法药物市场

第十七章：中国免疫疗法药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genscript Biotech Corporation
  • Gilead Sciences, Inc.
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Johnson & Johnson
  • Jubilant Life Sciences Limited
  • Labcorp
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-521BAA36EBB6

The Immunotherapy Drugs Market was valued at USD 222.59 billion in 2025 and is projected to grow to USD 251.56 billion in 2026, with a CAGR of 13.61%, reaching USD 543.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 222.59 billion
Estimated Year [2026] USD 251.56 billion
Forecast Year [2032] USD 543.82 billion
CAGR (%) 13.61%

This report opens with a concise framing of the contemporary immunotherapy landscape, clarifying the scope, objectives, and analytical approach taken to examine scientific advances, clinical evolution, regulatory developments, and commercial dynamics. It establishes the lenses through which subsequent analysis is presented, including clinical efficacy trends, manufacturing technology shifts, supply chain considerations, regulatory touchpoints, and stakeholder adoption drivers. By setting these parameters early, the narrative guides readers through interconnected themes that inform strategic decisions across research, clinical deployment, manufacturing scale-up, and market access.

Methodologically, the introduction explains the integration of primary expert interviews, clinical database reviews, regulatory documentation, patent analysis, and real-world evidence to build a coherent evidence base. It also outlines assumptions on data triangulation and the criteria used to evaluate technological maturity and adoption readiness. In doing so, the introduction positions the report as a pragmatic tool for decision-makers seeking to align scientific opportunity with operational capability and policy realities.

Transformative shifts reshaping immunotherapy research, manufacturing, commercialization and patient access that redefine clinical paradigms and investor priorities

Recent years have witnessed transformative shifts that are reshaping research priorities, commercialization pathways, and the delivery of immunotherapies to patients. Advances in precision cell engineering, such as next-generation receptor designs and allogeneic platforms, are enabling broader therapeutic concepts and the potential for off-the-shelf products. Concurrently, breakthroughs in vaccine platforms, oncolytic vectors, and immune modulators are being combined in multi-modal regimens, changing how clinical development strategies are designed and how regulatory engagement is approached. These scientific shifts are complemented by operational changes: modular manufacturing, single-use technologies, and distributed production models are redefining capacity planning and cost structures.

Moreover, financing models and investor sentiment have evolved from an emphasis on early discovery to validation of scalable manufacturing and durable clinical benefit, prompting companies to form strategic alliances and adapt go-to-market strategies. Patient access considerations are also shifting as health systems grapple with the integration of complex therapies into standard care pathways and as payers seek outcomes-linked approaches. Taken together, these developments redefine where value is created along the immunotherapy lifecycle and require stakeholders to rethink clinical design, supply chain resilience, reimbursement strategy, and long-term commercialization planning.

Cumulative implications of United States tariffs enacted in 2025 for immunotherapy supply chains, manufacturing, clinical trials, and patient access

The cumulative effect of United States tariff measures enacted in 2025 introduces a complex set of pressures across immunotherapy supply chains, manufacturing economics, and clinical operations. Tariff-related cost increases on imported reagents, specialized consumables, cell processing equipment, and certain biologic intermediates create direct operational headwinds for manufacturers and contract development and manufacturing organizations. Since many components of advanced therapy manufacturing remain globally sourced, these added costs can prompt strategic shifts including re-evaluation of supplier contracts, increased vertical integration, and accelerated localization efforts to mitigate exposure. In turn, manufacturing footprint decisions will increasingly weigh geopolitical risk alongside cost and regulatory considerations.

Beyond manufacturing, tariffs influence the economics of clinical trial operations by raising the cost of imported kits, cold-chain logistics, and outsourced laboratory services, which can extend timelines when sponsors seek alternate sources or requalify suppliers. Payers and health systems may also encounter upstream cost pressures that affect procurement strategies and adoption pathways for high-cost therapies. In response, industry stakeholders are likely to prioritize resilient sourcing strategies, diversify supplier bases, invest in domestic capacity where feasible, and engage proactively with procurement and policy stakeholders to clarify exemptions or mitigation mechanisms. Ultimately, while tariffs do not alter the scientific promise of immunotherapies, they reconfigure operational priorities and necessitate tactical adjustments across manufacturing, clinical, and commercial functions.

Actionable segmentation insights on therapy modalities, indication cohorts, administration routes, end users, and mechanisms for clinical and commercial planning

A nuanced understanding of segmentation is essential to align development strategies with clinical needs and commercial pathways. When considering therapy type, the landscape encompasses Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, Cytokines, and Oncolytic Virus Therapy. Within Adoptive Cell Therapy, attention must be paid to subcategories such as CAR-T therapy, NK cell therapy, and TCR-T therapy because each presents distinct manufacturing, regulatory, and delivery challenges. Cancer Vaccines span dendritic cell vaccines, DNA vaccines, and peptide vaccines, which differ in antigen selection, adjuvant needs, and administration logistics. Checkpoint Inhibitors include CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, each with unique efficacy and toxicity profiles that shape combination strategies. Cytokine approaches, including colony stimulating factors, interferons, and interleukins, continue to play roles as modulators of immune response and as components of combination regimens. Oncolytic Virus Therapy, covering adenovirus-based, herpesvirus-based, and reovirus-based platforms, presents specific considerations around vector design, manufacturing containment, and immune profiling.

From an indication perspective, segmentation across blood cancers, breast cancer, lung cancer, and melanoma reveals divergent clinical pathways and adoption dynamics. Blood cancer subtypes such as acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and lymphoma each demand tailored cell therapy and immunomodulatory approaches. Breast cancer segmentation into hormone receptor positive and triple negative categories reflects distinct biomarker-driven approaches and combination needs. Lung cancer differentiation between non-small cell and small cell disease affects target selection and trial design, while melanoma contexts such as cutaneous and uveal melanoma diverge in immune responsiveness. Route of administration considerations-intratumoral, intravenous, and subcutaneous-directly influence supply chain requirements, clinical infrastructure, and patient-centered care models. End users including hospitals, oncology clinics, and specialized centers will adopt therapies at different paces depending on capacity, clinician expertise, and reimbursement mechanisms. Finally, mechanisms of action framed as active immunotherapy, combination therapies, and passive immunotherapy are central to strategic prioritization: active approaches such as cancer vaccines and oncolytic virus therapy focus on inducing endogenous responses, whereas passive strategies like adoptive cell therapy, checkpoint inhibitors, and monoclonal antibodies rely on exogenous effector delivery or inhibition of inhibitory pathways. Collectively, these segmentation lenses inform prioritized development pathways, clinical trial design, and tailored commercialization strategies that reflect both scientific nuance and healthcare delivery realities.

Regional insights on adoption dynamics, infrastructure readiness, regulatory landscapes, and market access considerations across major global regions

Regional dynamics shape adoption trajectories, infrastructure readiness, regulatory engagement, and market access approaches across the globe. In the Americas, advanced therapy accelerators are visible in centers of excellence that combine academic leadership, manufacturing know-how, and payer engagement. These ecosystems support rapid clinical translation but also highlight the need for pragmatic strategies to integrate high-complexity therapies into routine care pathways and to negotiate value-based arrangements with payers.

In Europe, Middle East & Africa, regulatory harmonization efforts, national reimbursement frameworks, and diverse healthcare delivery systems create a spectrum of adoption environments. Capacity building for cell and gene therapy manufacturing and on-site clinical expertise varies widely, prompting tailored market entry strategies, regional manufacturing partnerships, and adaptive pricing approaches. In Asia-Pacific, rapid investment in biotechnology, growing clinical trial activity, and expanding domestic manufacturing capabilities are driving significant local innovation, even as regulatory pathways mature. Across all regions, infrastructure readiness-including GMP-compliant facilities, cold-chain logistics, and specialized clinical centers-remains a decisive factor in the pace of adoption, and stakeholders must align regional strategies with local regulatory and reimbursement realities to optimize patient access.

Competitive company insights examining pipeline composition, strategic alliances, manufacturing capabilities, regulatory positioning and commercialization pathways

Competitive dynamics in the immunotherapy space are characterized by a diverse mix of established pharmaceutical companies, biotechnology innovators, specialized contract manufacturers, and academic consortia. Companies with differentiated platforms that combine proprietary biology with scalable manufacturing advantage are positioned to lead, while organizations that invest in robust clinical evidence generation and real-world outcome measurement build long-term credibility with payers and clinicians. Strategic alliances, licensing deals, and targeted acquisitions remain central instruments for accelerating access to complementary capabilities such as vector production, cell processing automation, and companion diagnostics.

Manufacturing capability is an increasingly visible axis of competitive differentiation as leaders secure capacity, adopt automation, and form partnerships with specialized contract development and manufacturing organizations. Regulatory positioning and proactive engagement with authorities to shape approval pathways, especially for novel combination regimens and cell-based products, are critical. Moreover, companies that develop clear health economics narratives and engage early with value-assessment bodies enhance their prospects for reimbursement and broader adoption. Ultimately, competitive success will hinge on integrated execution across science, manufacturing, regulatory strategy, and payer engagement rather than on single-domain strength alone.

Practical and actionable strategic recommendations for industry leaders to accelerate clinical development, manufacturing resilience, and equitable patient access

Industry leaders should adopt a prioritized set of strategic actions to translate scientific progress into sustainable patient access. First, organizations must align clinical development with manufacturability by embedding process development earlier in discovery phases and by validating scalable, quality-by-design manufacturing approaches. This reduces downstream risk and enables more predictable regulatory interactions. Second, stakeholders should invest in supply chain resilience by diversifying suppliers, qualifying alternate sources, and exploring regional manufacturing partnerships to mitigate geopolitical or tariff-related disruptions.

Third, firms should engage payers, providers, and patient advocacy groups early to co-develop value demonstration frameworks that incorporate real-world outcomes and feasible payment models. Fourth, forging strategic alliances with technology providers, diagnostics developers, and clinical networks can accelerate time-to-clinic and broaden access. Fifth, companies should prioritize data infrastructure and interoperable systems to capture long-term outcomes and safety signals, which supports reimbursement negotiations and informs iterative product improvement. Finally, leaders must cultivate workforce capabilities in cell therapy manufacturing, regulatory affairs, and patient services to ensure that organizational capacity matches commercial ambition. Together, these recommendations create a practical roadmap for converting scientific breakthroughs into clinically and commercially viable therapies.

Rigorous mixed-methods research methodology integrating primary interviews, clinical database review, regulatory analysis, and real-world evidence synthesis

The research methodology employs a mixed-methods approach that integrates qualitative expert interviews with quantitative review of clinical registries, regulatory filings, and scientific literature. Primary research included structured consultations with clinical investigators, manufacturing leaders, regulatory specialists, payer representatives, and patient advocates to surface real-world challenges and adoption drivers. Secondary sources encompassed peer-reviewed journals, clinical trial registries, regulatory guidance documents, patent filings, and public disclosures to validate trends and triangulate insights.

Analytic techniques included thematic synthesis of interview findings, comparative analysis of regulatory pathways, and mapping of manufacturing and supply chain touchpoints. Real-world evidence analyses focused on treatment patterns, utilization barriers, and post-approval safety monitoring where publicly available data permitted. Throughout, emphasis was placed on transparent documentation of data provenance, conservative interpretation of datasets prone to bias, and iterative validation of conclusions with domain experts to enhance robustness and practical relevance.

Conclusive synthesis of findings, strategic significance, and priority actions underscoring the future trajectory of immunotherapy innovation and access

In conclusion, immunotherapy continues to advance across scientific and operational dimensions, and stakeholders must synthesize technological promise with pragmatic execution to realize patient impact. Scientific innovations-ranging from refined cell engineering and modular manufacturing to sophisticated vaccine and oncolytic platforms-are expanding therapeutic options, yet their translation into routine care depends on resilient manufacturing, data-driven reimbursement strategies, and regional alignment with infrastructure and regulatory frameworks. Tariff-driven cost pressures and geopolitical considerations add urgency to supply chain diversification and localization efforts, underscoring the need for strategic foresight.

As the field evolves, success will favor organizations that integrate cross-functional capabilities: aligning early development with manufacturing feasibility, engaging payers and providers to demonstrate value, building partnerships to accelerate commercialization, and investing in data systems that capture long-term outcomes. The pathway to broader patient access is not solely scientific; it is operational, strategic, and collaborative. Executives and clinical leaders who act now to strengthen these dimensions will be best positioned to translate immunotherapy innovation into meaningful, equitable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immunotherapy Drugs Market, by Therapy Type

  • 8.1. Adoptive Cell Therapy
    • 8.1.1. Car-T Therapy
    • 8.1.2. Nk Cell Therapy
    • 8.1.3. Tcr-T Therapy
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. Dna Vaccines
    • 8.2.3. Peptide Vaccines
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Cytokines
    • 8.4.1. Colony Stimulating Factors
    • 8.4.2. Interferons
    • 8.4.3. Interleukins
  • 8.5. Oncolytic Virus Therapy
    • 8.5.1. Adenovirus Based
    • 8.5.2. Herpesvirus Based
    • 8.5.3. Reovirus Based

9. Immunotherapy Drugs Market, by Route Of Administration

  • 9.1. Intratumoral
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. Immunotherapy Drugs Market, by Mechanism Of Action

  • 10.1. Active Immunotherapy
  • 10.2. Passive Immunotherapy

11. Immunotherapy Drugs Market, by End User

  • 11.1. Hospitals
  • 11.2. Oncology Clinics
  • 11.3. Specialized Centers

12. Immunotherapy Drugs Market, by Indication

  • 12.1. Blood Cancer
    • 12.1.1. Acute Lymphoblastic Leukemia
    • 12.1.2. Acute Myeloid Leukemia
    • 12.1.3. Chronic Lymphocytic Leukemia
    • 12.1.4. Lymphoma
  • 12.2. Breast Cancer
    • 12.2.1. Hormone Receptor Positive
    • 12.2.2. Triple Negative
  • 12.3. Lung Cancer
    • 12.3.1. NonSmallCell Lung Cancer
    • 12.3.2. SmallCell Lung Cancer
  • 12.4. Melanoma
    • 12.4.1. Cutaneous Melanoma
    • 12.4.2. Uveal Melanoma

13. Immunotherapy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Immunotherapy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immunotherapy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Immunotherapy Drugs Market

17. China Immunotherapy Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Bristol-Myers Squibb Company
  • 18.8. F. Hoffmann-La Roche Ltd
  • 18.9. Genscript Biotech Corporation
  • 18.10. Gilead Sciences, Inc.
  • 18.11. HD Biosciences Co., Ltd.
  • 18.12. Horizon Discovery Group PLC
  • 18.13. ImmunXperts SA
  • 18.14. Johnson & Johnson
  • 18.15. Jubilant Life Sciences Limited
  • 18.16. Labcorp
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. Pfizer Inc.
  • 18.20. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 279. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 283. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 285. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 288. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 291. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 292. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 293. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
  • TABLE 324. G7 IMMUNOTHERAPY DRUG